Organogenesis COO receives major equity grants

Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo reported new equity awards and related tax withholding transactions.

Rhea-AI Filing Summary

Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo reported new equity awards and related tax withholding transactions. He received a stock option covering 120,267 shares of Class A common stock and was granted or issued a total of 259,549 Class A shares through stock awards on February 18, 2026.

The equity awards include restricted stock units that vest in equal annual installments over four years beginning February 15, 2026, as well as shares issued from a 2025 performance share award based on achievement of performance milestones. In a separate transaction, 16,212 shares were disposed of at $3.84 per share to cover tax obligations tied to these awards.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Bilbo Patrick

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	120,267	$0.00	$0.00
Grant/Award	Class A Common Stock	210,937	$0.00	$0.00
Grant/Award	Class A Common Stock	48,612	$0.00	$0.00
Exercise Price or Tax Liability	Class A Common Stock	16,212	$3.84	$62K

Holdings After Transaction: Stock Option (Right to Buy) — 120,267 contracts (Direct); Class A Common Stock — 1,127,985 shares (Direct)

Footnotes (3)

1. F1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026.
2. F2. Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones.
3. F3. The option becomes exercisable in equal annual installments over four years beginning February 15, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Organogenesis (ORGO) report for Patrick Bilbo?

Patrick Bilbo reported equity awards and tax withholding transactions. He received option and stock awards in Organogenesis Class A shares, plus a small share disposition to cover tax obligations related to those grants and vesting events.

How many Organogenesis (ORGO) stock options were granted to Patrick Bilbo?

Patrick Bilbo was granted a stock option covering 120,267 shares of Organogenesis Class A common stock. This option becomes exercisable in equal annual installments over four years, beginning on February 15, 2026, providing a long-term incentive linked to company performance and retention.

How many Organogenesis (ORGO) shares did Patrick Bilbo acquire through stock awards?

Patrick Bilbo acquired 210,937 and 48,612 shares of Organogenesis Class A common stock through stock awards. These include restricted stock units with multi-year vesting and shares issued from a 2025 performance share award tied to the achievement of defined performance milestones.

What are the vesting terms for Patrick Bilbo’s Organogenesis RSUs and options?

The restricted stock units granted to Patrick Bilbo vest in equal annual installments over four years beginning February 15, 2026. His stock option also becomes exercisable in equal annual installments over four years from the same date, aligning vesting with long-term service and performance.

Why did Patrick Bilbo dispose of some Organogenesis (ORGO) shares in this filing?

Patrick Bilbo disposed of 16,212 shares of Organogenesis Class A common stock at $3.84 per share. This transaction was coded as a tax-withholding disposition, used to satisfy tax liabilities or exercise price obligations arising from his equity awards and vesting events.

What is Patrick Bilbo’s role at Organogenesis (ORGO) in this Form 4 filing?

In this Form 4, Patrick Bilbo is identified as the Chief Operating Officer of Organogenesis Holdings Inc. The reported transactions reflect equity compensation and related tax withholding in his capacity as a senior executive of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 05:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bilbo Patrick

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/18/2026		A		210,937(1)	A	$0	1,095,585	D
Class A Common Stock	02/18/2026		A		48,612(2)	A	$0	1,144,197	D
Class A Common Stock	02/18/2026		F		16,212	D	$3.84	1,127,985	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.84	02/18/2026		A		120,267		(3)	02/18/2036	Class A Common Stock	120,267	$0	120,267	D

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026.

2. Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones.

3. The option becomes exercisable in equal annual installments over four years beginning February 15, 2026.

	/s/ William R. Kolb, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.